



Edwards

Edwards SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra Adaptive Prestant

Instructions for Use - Pulmonic

CAUTION: Federal (USA) law restricts these devices to sale by or on the order of a physician.

Implantation of the transcatheter heart valve and the adaptive prestant should be performed only by physicians who have received Edwards Lifesciences training. The implanting physician should be experienced in balloon valvuloplasty.

Please verify that you have the latest version of the instructions for use prior to using the device by visiting <http://eifu.edwards.com/> or by calling 1.888.570.4016.

STERILE: The valve is supplied sterilized with glutaraldehyde solution. The delivery system, sheath, and crimper are supplied sterilized with ethylene oxide gas. The Edwards Alterra adaptive prestant system is supplied sterilized with e-beam sterilization.


1.0 Device Description

Edwards SAPIEN 3 Transcatheter Pulmonary Valve (TPV) System with Alterra Adaptive Prestant

The Edwards SAPIEN 3 transcatheter pulmonary valve system with Alterra adaptive prestant consists of the Edwards 29-mm SAPIEN 3 transcatheter heart valve (THV), the Edwards SAPIEN 3 transcatheter pulmonic valve delivery system (PDS), the Edwards Alterra adaptive prestant system and accessories.

• Edwards SAPIEN 3 Transcatheter Heart Valve (Figure 1)

The Edwards SAPIEN 3 transcatheter heart valve is comprised of a balloon-expandable, radiopaque, cobalt-chromium frame, trileaflet bovine pericardial tissue valve, and polyethylene terephthalate (PET) fabric skirt. The leaflets are treated according to the Carpentier-Edwards ThermaFix process.



9600TFX

Figure 1: Edwards SAPIEN 3 Transcatheter Heart Valve

Table 1

Valve Size	Valve Height
29 mm	22.5 mm

• Edwards SAPIEN 3 Transcatheter Pulmonic Valve Delivery System (Figures 2, 3, 4)

The Edwards SAPIEN 3 Transcatheter Pulmonic Valve Delivery System (29 mm PDS), 29 mm (Figure 2) facilitates the placement of the bioprosthesis. It consists of an inline sheath, balloon catheter for deployment of the Edwards SAPIEN 3 transcatheter heart valve, radiopaque markers on the balloon catheter, and an outer shaft and valve capsule to cover the transcatheter heart valve during insertion and tracking to the intended deployment location. The delivery system includes a tapered tip to facilitate crossing of right heart structures. The valve capsule and tapered tip are hydrophilic coated. A visual balloon shaft marker is provided to assist with balloon recapture. A stylet is included within the guidewire lumen of the delivery system. The 28F hydrophilic coated dilator (packaged with the delivery system) is used to predilate the vessel prior to insertion of the delivery system, if necessary (Figure 3). The inflation parameters for the valve deployment are shown in the table below:

Table 2

Model	Nominal Balloon Diameter	Nominal Inflation Volume	Rated Burst Pressure (RBP)
9631PL29	30 mm	29 ml	9 atm (912 kPa)




Figure 2: Edwards SAPIEN 3 Transcatheter Pulmonic Valve Delivery System, 29 mm

• Edwards Alterra Adaptive Presept System

Refer to the Edwards Alterra adaptive presept system instructions for use.

Additional Accessories




Figure 3: 28F Dilator




Figure 4: Qualcrimp Crimping Accessory

• Dilator

The dilator allows physicians to predilate the access site prior to valve delivery system insertion.

• Edwards Sheath

Refer to the provided Edwards sheath instructions for use for device description.

- **Edwards Crimper**

Refer to the Edwards Crimper instructions for use for device description.

2.0 Indications

The Edwards SAPIEN 3 transcatheter pulmonary valve system with Alterra adaptive pre-stent is indicated for use in the management of pediatric and adult patients with severe pulmonary regurgitation as measured by echocardiography who have a native or surgically-repaired right ventricular outflow tract and are clinically indicated for pulmonary valve replacement.

3.0 Contraindications

The Edwards SAPIEN 3 transcatheter pulmonary valve system with Alterra adaptive pre-stent is contraindicated in patients who cannot tolerate an anticoagulation/antiplatelet regimen or who have active bacterial endocarditis or other active infections.

4.0 Warnings

- The devices are designed, intended, and distributed for single use only. **Do not resterilize or reuse the devices.** There are no data to support the sterility, nonpyrogenicity, and functionality of the devices after reprocessing.
- The physician must verify correct orientation of the valve prior to its implantation; the inflow (outer skirt end) of the valve should be oriented towards the proximal end (handle) of the delivery system to prevent the risk of severe patient harm.
- Prior to delivery, the valve must remain hydrated at all times and cannot be exposed to solutions other than its shipping storage solution and sterile physiologic rinsing solution. Valve leaflets mishandled or damaged during any part of the procedure will require replacement of the valve.
- Do not use the valve if the tamper evident seal is broken, the storage solution does not completely cover the valve, the temperature indicator has been activated, the valve is damaged, or the expiration date has elapsed.
- Do not mishandle the delivery system or use it if the packaging or any components are not sterile, have been opened or are damaged (e.g., kinked or stretched), or the expiration date has elapsed.
- Do not add or apply antibiotics to the storage solution, rinse solutions or to the valve.
- Care should be exercised in patients with hypersensitivities to cobalt, nickel, chromium, molybdenum, titanium, manganese, silicon, and/or polymeric materials.

5.0 Precautions

- Long-term durability has not been established for the valve. Regular medical follow-up is advised to evaluate valve performance.
- Accelerated deterioration of the valve may occur in patients with an altered calcium metabolism.
- Assessment for coronary compression risk prior to implantation is recommended.
- Patient venous anatomy should be evaluated to prevent the risk of access that would preclude the delivery and deployment of the device.
- Use of excessive contrast media may lead to renal failure. Measure the patient's creatinine level prior to the procedure. Contrast media usage should be monitored.
- Fluoroscopically guided procedures are associated with a risk of radiation injury to the skin. Patient radiation dose should be monitored during the procedure.
- Glutaraldehyde may cause irritation of the skin, eyes, nose and throat. Avoid prolonged or repeated exposure to, or breathing of, the solution. Use only with adequate ventilation. If skin contact occurs, immediately flush the affected area with water; in the event of contact with eyes, seek immediate medical attention. For more information about glutaraldehyde exposure, refer to the Material Safety Data Sheet available from Edwards Lifesciences.
- Patient should be heparinized to maintain the ACT at ≥ 250 sec prior to introduction of the delivery system in order to prevent thrombosis.
- To maintain proper valve leaflet coaptation, do not overinflate the deployment balloon.
- Valve recipients should be maintained on anticoagulant/antiplatelet therapy, except when contraindicated, as determined by their physician. This device has not been tested for use without antiplatelet therapy.
- It is recommended that all prosthetic heart valve recipients be prophylactically treated for endocarditis to minimize the possibility of prosthetic valve infection.
- Safety and effectiveness have not been established for patients with the following characteristics/comorbidities:
 - Blood dyscrasias defined as: leukopenia, acute anemia, thrombocytopenia, or history of bleeding diathesis or coagulopathy
 - A known hypersensitivity or contraindication to aspirin, heparin, ticlopidine (Ticlid[™]), or clopidogrel (Plavix[™]), or sensitivity to contrast media, which cannot be adequately premedicated

-
- Positive urine or serum pregnancy test in female patients of child-bearing potential

6.0 Potential Adverse Events

Potential risks associated with the anesthesia, interventional procedure and imaging include but are not limited to:

- Death
- Stroke/transient ischemic attack
- Respiratory insufficiency or respiratory failure
- Cardiovascular or vascular injury, such as perforation or damage (dissection) of vessels, myocardium or valvular structures including rupture of the RVOT that may require intervention
- Pericardial effusion/cardiac tamponade
- Cardiac failure
- Embolic event: air, calcific material, thrombus, device fragments
- Infection including incisional site infection, septicemia and endocarditis
- Myocardial infarction
- Renal insufficiency or renal failure
- Conduction system injury
- Arrhythmia
- Deep vein thrombosis
- Arteriovenous (AV) fistula
- Systemic or peripheral nerve injury
- Systemic or peripheral ischemia
- Pulmonary edema
- Pneumothorax
- Pleural effusion
- Dyspnea
- Atelectasis
- Dislodgement of previously implanted devices (i.e., pacing lead)
- Blood loss requiring transfusion
- Anemia
- Radiation injury
- Electrolyte imbalance
- Hypertension or hypotension
- Allergic reaction to anesthesia, contrast media, antithrombotic therapy, device materials
- Hematoma or ecchymosis
- Syncope
- Pain
- Exercise intolerance or weakness
- Inflammation
- Angina
- Fever

Potential risks that may or may not require intervention associated with the valve, delivery system and/or accessories include, but may not be limited to, the following:

- Cardiac arrest
- Cardiogenic shock
- Coronary flow obstruction/transvalvular flow disturbance
- Device thrombosis
- Injury to tricuspid valve
- Device embolization
- Device acute migration or malposition
- Endocarditis
- Chest pain/discomfort
- Hemolysis / hemolytic anemia

- Device dysfunction (regurgitation and/or stenosis)
- Aortic root distortion
- Embolic event: device fragments
- Mechanical failure of delivery system, and/or accessories

See Section 12 for adverse events that occurred in the clinical study.

7.0 Directions for Use

7.1 System Compatibility

Table 3

Product Name	Model
Edwards SAPIEN 3 Transcatheter Heart Valve (29 mm)	9600TFX29
Edwards SAPIEN 3 Transcatheter Pulmonic Valve Delivery System ^[1]	9631PL29
Sheath provided by Edwards Lifesciences	
Inflation device, Qualcrimp crimping accessory, Crimp Stopper provided by Edwards Lifesciences	
Edwards Crimper	9600CR
Edwards Alterra Adaptive Prestent System ^[2]	29AP4045

^[1] Includes a 28F Dilator

^[2] Includes an Alterra adaptive prestent that is fully loaded in an Alterra delivery system

Additional Equipment:

- Balloon tip catheter
- Sizing balloons
- 20 cc syringe or larger (x2)
- 50 cc syringe or larger
- High-pressure 3-way stopcock
- Standard cardiac catheterization lab equipment
- Fluoroscopy (appropriate for use in percutaneous coronary interventions)
- Exchange length 0.035 inch (0.89 mm) stiff guidewire
- Sterile rinsing basins; physiological saline, heparinized saline, and 15% diluted radiopaque contrast medium
- Sterile table for valve and device preparation

7.2 Edwards Alterra Adaptive Prestent System Procedure

See Edwards Alterra adaptive prestent system instructions for use for device preparation and implantation prior to transcatheter heart valve preparation and deployment.

Prior to valve implantation, assess Alterra prestent stability by evaluating apices engagement in surrounding tissue, wall apposition, and/or motion of prestent within the anatomy. If adequate stability is not noted, consider staging valve deployment after allowing sufficient time for prestent endothelialization.

CAUTION: Failure to identify prestent instability may lead to prestent migration/embolization when tracking interventional devices through the prestent.

7.3 Valve Handling and Preparation

Follow sterile technique during device preparation and implantation.

7.3.1 Valve Rinsing Procedure

Before opening the valve jar, carefully examine for evidence of damage (e.g., a cracked jar or lid, leakage, or broken or missing seals).

CAUTION: Valves from containers found to be damaged, leaking, without adequate sterilant, or missing intact seals must not be used for implantation.

1. Set up two (2) sterile bowls with at least 500 ml of sterile physiological saline to thoroughly rinse the glutaraldehyde sterilant from the valve.

-
- Carefully remove the valve/holder assembly from the jar without touching the tissue. Verify the valve serial identification number with the number on the jar lid and record in the patient information documents. Inspect the valve for any signs of damage to the frame or tissue.
 - Rinse the valve as follows: Place the valve in the first bowl of sterile, physiological saline. Be sure the saline solution completely covers the valve and holder. With the valve and holder submerged, slowly agitate (to gently swirl the valve and holder) back and forth for a minimum of 1 minute. Transfer the valve and holder to the second rinsing bowl of physiological saline and gently agitate for at least one more minute. Ensure the rinse solution in the first bowl is not used. The valve should be left in the final rinse solution until needed to prevent the tissue from drying.

CAUTION: Do not allow the valve to come into contact with the bottom or sides of the rinse bowl during agitation or swirling in the rinse solution. Direct contact between the identification tag and valve is also to be avoided during the rinse procedure. No other objects should be placed in the rinse bowls. The valve should be kept hydrated to prevent the tissue from drying.

7.3.2 Prepare the System

Refer to the Edwards sheath, Edwards Crimper instructions for use for device preparation.

- Visually inspect all the components for damage. Ensure the handle is fully retracted to the gripper.
Note: The delivery system is packaged with a balloon cover placed over the balloon and should not be removed until instructed to do so.
- Remove the stylet from the distal end of the guidewire lumen and set aside.
- Flush the guidewire lumen with heparinized saline. Insert the stylet back into the guidewire lumen.
CAUTION: Failure to replace the stylet in the guidewire lumen may result in damage to the lumen during the crimping process.
- Attach a 3-way stopcock to the balloon inflation port. Ensure stopcock is tightened securely. Fill a 50 cc or larger syringe with 15-20 ml of diluted contrast medium and attach to the 3-way stopcock.
- Fill the inflation device provided by Edwards Lifesciences with excess volume of diluted contrast medium relative to the indicated inflation volume. Lock and attach to the 3-way stopcock.
- Close stopcock to the inflation device. De-air the system using the 50 cc or larger syringe. Slowly release the plunger and return to neutral pressure.
Note: Do not remove the balloon cover during de-airing.
Note: May take multiple negative pulls to de-air the balloon catheter.
- Close stopcock to the delivery system and de-air the inflation device. By rotating the knob of the inflation device, transfer the contrast medium into the syringe to achieve the appropriate volume required to deploy the valve per the inflation parameters.
- Verify that the inflation volume in the inflation device is correct. Close the stopcock to the 50 cc or larger syringe. Lock the inflation device and remove the syringe. Verify stopcock is securely attached to the balloon inflation port.
CAUTION: Maintain the inflation device provided by Edwards Lifesciences in the locked position until valve deployment.

7.3.3 Mount and Crimp the Valve on the Delivery System

- Set up two (2) additional sterile bowls with at least 100 ml of sterile physiological saline to thoroughly rinse the Qualcrimp crimping accessory.
- Completely submerge the Qualcrimp crimping accessory in the first bowl and gently compress it to ensure complete saline absorption. Slowly swirl the Qualcrimp crimping accessory for a minimum of 1 minute. Repeat this process in the second bowl.
- Remove crimper from packaging. Rotate the crimper handle until the aperture is fully open. Attach the 2-piece crimp stopper to the base of the crimper and click into place.
- Carefully remove the balloon cover from the delivery system. Visually inspect the balloon for damage. Ensure that the stylet is inserted into the guidewire lumen.
- Remove the valve from the holder and remove the ID tag.
- With the crimper in the open position, gently place the valve into the crimper aperture. Partially crimp the valve until it fits into the Qualcrimp crimping accessory.
- Place the Qualcrimp crimping accessory over the valve making sure the edge of the Qualcrimp crimping accessory is parallel to the inflow of the valve.
- Place the valve and Qualcrimp crimping accessory in crimper aperture. Insert the delivery system coaxially within the valve with the orientation of the valve on the delivery system with the inflow (outer sealing skirt) of the valve towards the handle.
Note: Verify correct valve orientation with the inflow (outer sealing skirt) oriented towards the handle.
- Crimp the valve between the internal shoulders until it reaches the Qualcrimp stop located on the 2-piece crimp stopper.
- Gently remove the Qualcrimp crimping accessory from the valve. Remove the Qualcrimp stop from the crimp stopper, leaving the final stop in place.

11. Center the valve within the crimper aperture. Fully crimp the valve until it reaches the final stop and hold for 5 seconds. Repeat this crimp step three (3) more times for a total of 4 crimps.
Note: Ensure the valve is coaxial within the crimper aperture and remains between the two internal shoulders of the delivery system.
WARNING: The physician must verify correct orientation of the valve prior to its implantation.
12. Flush the outer shaft with heparinized saline through the flush port on the handle.
13. Cover the crimped valve with the valve capsule by retracting the balloon catheter into the outer shaft. Ensure that the distal edge of the valve capsule meets the tapered tip of the delivery system.
CAUTION: Keep valve hydrated until ready for implantation.
14. Lock the delivery system.
15. Remove the stylet and flush the guidewire lumen of the delivery system.
16. Flush the inline sheath with heparinized saline. Immediately advance the inline sheath until the sheath tip is against the proximal end of the valve capsule.
Note: Do not force the inline sheath over the valve capsule.
17. Hydrate the tapered tip and valve capsule of delivery system with heparinized saline.
18. Flush and hydrate the dilator.

7.4 Valve Delivery

Valve delivery should be performed under local and/or general anesthesia with hemodynamic monitoring in a catheterization lab/hybrid operating room with fluoroscopic imaging capabilities.

CAUTION: Use of excessive contrast media may lead to renal failure. Measure the patient's creatinine level prior to the procedure. Contrast media usage should be monitored.

1. If necessary, gain access using standard catheterization techniques.
2. Ensure tapered tip and valve capsule of delivery system are hydrated, and the delivery system is locked.
3. If not present, insert the guidewire into the vasculature. Advance the guidewire into the intended landing zone per standard technique.
4. If necessary, remove existing sheath.
5. Predilate the vessel with the provided dilator to prepare the vasculature for insertion and advancement of the delivery system and inline sheath.
6. Introduce the delivery system and inline sheath, until the inline sheath is fully inserted into the vasculature.
7. Continue to advance the delivery system while maintaining inline sheath position and advance to the intended landing zone.
CAUTION: Use caution when advancing devices/delivery systems into the implanted Alterra adaptive prestant to avoid engagement with the inflow apices.
8. Position the valve within the waist of the Alterra adaptive prestant using the waist markers.
9. When at the intended landing zone, unlock the delivery system. Unsheathe the valve by retracting the outer shaft while maintaining balloon and inline sheath position. The valve is fully uncovered when the handle meets the gripper. Lock the delivery system. Verify the stopcock is securely attached to the balloon inflation port.
CAUTION: Maintain guidewire position in the pulmonary artery during valve unsheathing to prevent loss of guidewire position.
10. Verify final position and begin valve deployment:
 - a) Unlock the inflation device provided by Edwards Lifesciences.
 - b) Using slow controlled inflation, deploy the valve with the entire volume in the inflation device, hold for 3 seconds and confirm that the barrel of the inflation device is empty to ensure complete inflation of the balloon.
 - c) Deflate the balloon.

7.5 System Removal

1. Once the balloon is fully deflated, ensure the handle is in the locked position, and retract the delivery system into the vena cava.
2. Unlock the delivery system, retract the balloon into the valve capsule.
CAUTION: Completely cover the balloon prior to removal to minimize the risk of vascular injury.
3. Lock the delivery system.
4. Remove all devices when the ACT level is appropriate. Continue to remove the delivery system until the valve capsule meets the inline sheath tip.
Remove the inline sheath and the delivery system together.
Note: A sheath or other device may need to be inserted per standard of care.

5. Remove all devices when the ACT level is appropriate.

Close the access site.

8.0 How Supplied

STERILE: The valve is supplied sterilized with glutaraldehyde solution. The delivery system, sheath, and crimper are supplied sterilized with ethylene oxide gas. The Edwards Alterra adaptive prestant system is supplied pouched and sterilized by e-beam sterilization.

8.1 Storage

The transcatheter heart valve must be stored at 10 °C - 25 °C (50 °F - 77 °F). The delivery system and accessories should be stored in a cool, dry place. The prestant and delivery system must be stored in a cool, dry place.

9.0 Magnetic Resonance (MR) Safety Information



MR Conditional

A person with the Edwards Alterra adaptive prestant, alone or with a deployed SAPIEN 3 transcatheter heart valve implant may be safely scanned under the following conditions. Failure to follow these conditions may result in injury.	
Device Name	Edwards Alterra adaptive prestant in conjunction with Edwards SAPIEN 3 transcatheter heart valve
Static Magnetic Field Strength (B0)	1.5 tesla (T) or 3.0 tesla (T)
Maximum Spatial Field Gradient	3000 gauss/cm (30 T/m) or less
RF Excitation	Circularly Polarized (CP) / Multichannel-2 (MC-2)
RF Transmit Coil Type	There are no Transmit Coil restrictions
Operating Mode	Normal Operating Mode
Maximum Whole-Body SAR	2.0 W/kg
Scan Duration	2.0 W/kg whole-body average SAR for 15 minutes of continuous RF (a sequence or back to back series/scan without breaks)
MR Image Artifact	The presence of this implant may produce an image artifact.

10.0 Patient Information

Patient education brochures are provided to each site and should be given to the patient to inform them of the risks and benefits of the procedure and alternatives in adequate time before the procedure to be read and discussed with their physician. A copy of this brochure may also be obtained from Edwards Lifesciences by calling 1.800.822.9837. A patient implant card request form is provided with each transcatheter heart valve and prestant. After implantation, all requested information should be completed on this form. The serial number may be found on the package and on the identification tag attached to the transcatheter heart valve. The lot number may be found on the prestant package. The original form should be returned to the Edwards Lifesciences address indicated on the form and upon receipt, Edwards Lifesciences will provide an identification card to the patient.

11.0 Recovered Valve, Prestent and Device Disposal

The explanted valve should be placed into a suitable histological fixative such as 10% formalin or 2% glutaraldehyde and returned to the company. The explanted prestant should be placed into a suitable container and returned to the company. Refrigeration is not necessary under these circumstances. Contact Edwards Lifesciences to request an Explant Kit.

Used devices may be handled and disposed of in the same manner as hospital waste and biohazardous materials. There are no special risks related to the disposal of these devices.

12.0 Clinical Studies

SUMMARY OF CLINICAL STUDY

Patients were enrolled between August 2017 and September 2019 at 11 investigational sites in the U.S. An additional 25 patients were enrolled in a registry between January 2020 and August 2020 to evaluate use of the Pulmonic Delivery System at 13 investigational sites. The database for this PMA reflected data collected through June 2, 2021.

The Alterra Clinical Study used an independent Data Safety Monitoring Board (DSMB) that was instructed to notify the applicant of any safety or compliance issues and a Clinical Events Committee (CEC) that was responsible for adjudicating endpoint-related events reported during the study. An independent echocardiographic core laboratory was used for standardized assessment of echocardiograms.

Clinical Inclusion and Exclusion Criteria

Enrollment in the Alterra Clinical Study was limited to patients who met the following inclusion criteria:

- The candidate/candidate's legal guardian has been informed of the nature of the study, agrees to its provisions and has provided written informed consent
- Weight is ≥ 20 kg (44 lbs)
- RVOT/pulmonary valve (PV) with moderate or greater PR by transthoracic echocardiogram (TTE)
- RVOT/PV proximal and distal landing zone diameter ≥ 27 mm and ≤ 38 mm, and minimum of 35 mm from contractile tissue to lowest pulmonary artery takeoff

Patients were not permitted to enroll in the study if they met any of the following exclusion criteria:

- Active infection requiring current antibiotic therapy (if temporary illness, patient may be a candidate 2 weeks after discontinuation of antibiotics)
- History of or active endocarditis (active treatment with antibiotics) within the past 180 days
- Leukopenia (white blood cell (WBC) < 2000 cells/ μ L), anemia (hemoglobin (Hgb) < 7 g/dL), thrombocytopenia (platelets $< 50,000$ cells/ μ L) or any known blood clotting disorder
- Inappropriate anatomy for introduction and delivery of Alterra or the SAPIEN 3
- Need for concomitant atrial septal defect or ventricular septal defect closure or other concomitant interventional procedures other than pulmonary artery or branch pulmonary artery stenting or angioplasty
- Interventional/surgical procedures within 30 days prior to the Alterra or valve implant procedure
- Any planned surgical, percutaneous coronary or peripheral procedure to be performed within the 30-day follow-up from the Alterra or valve implant procedure
- History of or current intravenous drug use
- Major or progressive non-cardiac disease resulting in a life expectancy of less than one year
- Known hypersensitivity to aspirin or heparin and cannot be treated with other antiplatelet and/or antithrombotic medications
- Known hypersensitivity to nitinol, cobalt-chromium, nickel or contrast media that cannot be adequately pre-medicated
- Currently participating in an investigational drug or another device study [Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational devices.]
- Positive urine or serum pregnancy test in female patients of child-bearing potential
- Renal insufficiency (creatinine > 3.0 mg/dL) and/or renal replacement therapy

Clinical Endpoints

The endpoints analyzed in this application included: valve performance based on echocardiographic data, RVOT reintervention, adjudicated adverse events (device embolization, major vascular complications, life-threatening or disabling bleeding, device-related endocarditis and death), successful delivery of the pre-stent and valve to the intended location, freedom from device explant, site reported adverse events, and New York Heart Association (NYHA) classification. The analyses in the application focused on the 30-day and 6-month time points.

A. Accountability of the PMA Main Cohort

At the time of database lock, a total of 85 patients were enrolled in the study, including 60 in the main cohort and 25 in the PDS registry cohort.

There were 3 different analysis populations defined in the protocol: All Treated (AT), Attempted Implant (AI), and Valve Implant (VI), as summarized in Table 4.

Table 4: Analysis Populations

Analysis Population	Definition	Number of Patients	
		Main Cohort	PDS Registry
All Treated (AT)	All patients who signed informed consent, passed screening and for whom the procedure was begun (defined as the time of vascular access - incision or puncture).	60	25

Analysis Population	Definition	Number of Patients	
		Main Cohort	PDS Registry
Attempted Implant (AI)	All AT patients who had an attempted implant (the introducer sheath for vascular delivery of the Alterra adaptive pre-stent was inserted).	60	25
Valve Implant (VI)	All AI patients who received and retained a SAPIEN 3 THV upon leaving the catheterization laboratory/hybrid suite.	60	25

Study visit compliance is summarized in Table 5. One patient in the main cohort had not completed the 6-month at the time of the database lock.

Table 5: Study Visit Compliance

	Main Cohort (N=60)		PDS Registry (N=25)	
	30 Days	6 Months	30 Days	6 Months
Ineligible *	0	0	1	1
Eligible	60	60	24	24
Visit completed	60 (100.0%)	59 (98.3%)	24 (100%)	23 (95.8%)

*Ineligible patients included those who had died, withdrawn, lost to follow-up, or not reached the visit window.

B. Study Population Demographics and Baseline Characteristics

The demographics and baseline characteristics of the study population are typical for a transcatheter pulmonary valve study performed in the U.S., as shown in Table 6.

Table 6: Demographics and Baseline Characteristics (AT Population)

Demographics and Baseline Characteristics	Summary Statistics*	
	Main Cohort (N=60)	PDS Registry (N=25)
Age (years)	29.5 ± 2.14 (60)	29.1 ± 3.45 (25)
<12 years (child)	1.7% (1/60)	0.0% (0/25)
12-21 years (adolescent)	48.3% (29/60)	44.0% (11/25)
>21 years (adult)	50.0% (30/60)	56.0% (14/25)
Male Sex	56.7% (34/60)	56.0% (14/25)
Weight (kg)	73.1 ± 3.05 (60)	73.7 ± 4.44 (25)
New York Heart Association (NYHA) Class		
Class I	53.3% (32/60)	37.5% (9/24)
Class II	38.3% (23/60)	45.8% (11/24)
Class III	8.3% (5/60)	16.7% (4/24)
Class IV	0.0% (0/60)	0.0% (0/24)
NYHA Class Grouped		
Class I/II	91.7% (55/60)	83.3% (20/24)
Class III/IV	8.3% (5/60)	16.7% (4/24)
Primary diagnosis		
Pulmonary atresia	5.0% (3/60)	4.0% (1/25)
Pulmonary valve stenosis	23.3% (14/60)	20.0% (5/25)
Tetralogy of Fallot	70.0% (42/60)	68.0% (17/25)
Other	1.7% (1/59)	8.0% (2/25)
Secondary diagnosis		
Atrial septal defect	18.3% (11/60)	12.0% (3/25)
Coarctation of the aorta	3.3% (2/60)	4.0% (1/25)

Demographics and Baseline Characteristics	Summary Statistics*	
	Main Cohort (N=60)	PDS Registry (N=25)
Ventricular septal defect	30.0% (18/60)	12.0% (3/25)
Other	21.7% (13/60)	20.0% (5/25)
Most recent RVOT/PV intervention or surgery		
Pericardial/transannular patch	65.0% (39/60)	60.0% (15/25)
Valvuloplasty alone	25.0% (15/60)	20.0% (5/25)
Other†	10.0% (6/60)	20.0% (5/25)

*Continuous measures - mean ± SD (total no.); categorical measures - % (no./total no.)

†Tetralogy of Fallot repairs, unspecified RVOT/PV procedures, or none.

The breakdowns of prior cardiac interventions by patient age in the AT population are shown in Table 7 for the main cohort and Table 8 for the PDS registry cohort.

Table 7: Prior Cardiac Interventions by Age Group (AT Population) – Main Cohort

Most Recent RVOT/PV Intervention or Surgery	Summary Statistics*		
	<12 Years (N=1)	12-21 Years (N=29)	≥22 Years (N=30)
Pericardial/transannular patch	100.0% (1/1)	82.8% (24/29)	46.7% (14/30)
Valvuloplasty alone	0.0% (0/1)	17.2% (5/29)	33.3% (10/30)
Other	0.0% (0/1)	0.0% (0/29)	20.0% (6/30)
Tetralogy of Fallot repairs	0.0% (0/0)	0.0% (0/29)	66.7% (4/6)
Unspecified RVOT/PV procedure	0.0% (0/0)	0.0% (0/29)	16.7% (1/6)
None	0.0% (0/0)	0.0% (0/29)	16.7% (1/6)

*Event rate (no./total no.)

Table 8: Prior Cardiac Interventions by Age Group (AT Population) – PDS Registry

Most Recent RVOT/PV Intervention or Surgery	Summary Statistics*	
	12-21 Years (N=11)	≥22 Years (N=14)
Pericardial/transannular patch	72.7% (8/11)	50.0% (7/14)
Valvuloplasty alone	18.2% (2/11)	21.4% (3/14)
Other	9.1% (1/11)	28.6% (4/14)
Tetralogy of Fallot repairs	100.0% (1/1)	25.0% (1/4)
Unspecified RVOT/PV procedure	0.0% (0/1)	50.0% (2/4)
None	0.0% (0/1)	25.0% (1/4)

*Event rate (no./total no.)

A. Safety and Effectiveness Results

(1) Primary Endpoint

The primary endpoint result for the main cohort is presented in Table 9. The rate of THV dysfunction at 6 months was 0% (two-sided confidence interval: 0.0% to 6.1%). Since the upper limit of the two-sided 95% confidence interval for the primary endpoint event rate was < 25%, the endpoint was met.

Table 9: Primary Endpoint Result - Main Cohort

Endpoint	Summary Statistics* (N=60)	95% Confidence Interval †	Less Than Prespecified Performance Goal (25%)?
Valve dysfunction‡	0.0% (0/59)	[0.0%, 6.1%]	Yes
RVOT/PV reintervention	0.0% (0/60)		
Moderate or greater pulmonary regurgitation	0.0% (0/59)		
Mean RVOT gradient ≥35 mmHg	0.0% (0/59)		

*Event rate (no./total no.)

†One patient did not have evaluable echocardiogram data.

‡Two-sided 95% confidence interval.

The primary endpoint result for the PDS registry cohort is presented in Table 10. Acute PDS success was achieved in 88.0% of the patients.

Table 10: Primary Endpoint Results - PDS Registry

Endpoint	Summary Statistics* (N=25)
Acute PDS success*	88.0% (22/25)
Single THV implanted in the desired location	100.0% (25/25)
RV-PA peak-to-peak gradient < 35 mmHg post implantation	100.0% (25/25)
Less than moderate PR by discharge TTE (or earliest evaluable TTE)	88.0% (22/25)
Free of explant at 24 hours post implantation	100.0% (25/25)

*Event rate (no./total no.)

(2) Additional Outcome Measures

Technical Success

Technical success at exit from the procedure room was achieved in 96.7% of the patients in the main cohort, as summarized in Table 11.

Table 11: Technical Success Result - Main Cohort

Endpoint	Summary Statistics* (N=60)
Technical Success	96.7% (58/60)
Alive	100.0% (60/60)
Successful access delivery and retrieval of the Alterra delivery system	100.0% (60/60)
Successful access delivery and retrieval of the SAPIEN 3 delivery system	100.0% (60/60)
Single Alterra deployed in the desired location	100.0% (60/60)
Single SAPIEN 3 valve deployed to the desired location	96.7% (58/60)
No need for unplanned or emergency surgery or intervention related to the device or access procedure	100.0% (60/60)

*Event rate (no./total no.)

Device Success

The device success rate in the main cohort was 88.3% at 30 days, and 76.3% at 6 months, as summarized in Table 12.

Table 12: Device Success Results - Main Cohort

Endpoint	Summary Statistics*	
	30 Days (N=60)	6 Months (N=59)
Device Success	88.3% (53/60)	76.3% (45/59)
Alive	100.0% (60/60)	100% (59/59)
No device explant	100.0% (60/60)	100% (59/59)
No additional surgical or interventional procedures related to access or the device since completion of the original procedure	100.0% (60/60)	100% (59/59)
Intended performance of the device [†]	88.3% (53/60)	76.3% (45/59)
Structural performance [‡]	90.0% (54/60)	76.3% (45/59)
Hemodynamic performance	100.0% (60/60)	100% (59/59)
Absence of para-device complications	98.3% (59/60)	100% (59/59)

*Event rate (no./total no.)

[†]Intended performance of the device is defined as a composite of: (1) structural performance - no migration, embolization, fracture, thrombosis (including reduce leaflet mobility if detected) or endocarditis; (2) hemodynamic performance - net pulmonary valve peak gradient \leq 35 mmHg and transvalvular PR \leq mild; and (3) absence of para-device complications – pulmonary valve regurgitation $>$ mild, need for a permanent pacemaker, or new pulmonary embolism.

[‡]The structural performance events included 4 Alterra Prestent fracture events, 1 SAPIEN 3 THV thrombosis event, 1 Alterra Prestent thrombosis event, and 1 Alterra Prestent migration event at 30 days and an additional 8 Alterra Prestent fracture events at 6 months. Multiple events occurred on one patient are counted as one.

Procedural Success

Procedural success was met in 88.3% of patients in the main cohort at 30 days, as summarized in Table 13.

Table 13: Procedure Success Result - Main Cohort


Endpoint	Summary Statistics* (N=60)
Procedure Success	88.3% (53/60)
Device success	88.3% (53/60)
No device or procedure related SAEs [†]	100.0% (60/60)

*Event rate (no./total no.)

[†]SAEs: life threatening bleed; major vascular or access site complications requiring unplanned reintervention or surgery; stage 2 or 3 acute kidney injury (including new dialysis); severe heart failure or hypotension requiring intravenous inotrope, ultrafiltration or mechanical circulatory support; prolonged intubation $>$ 48 hours.


THV Hemodynamic Function

The mean RVOT gradient, peak RVOT gradient, total PR, and paravalvular regurgitation results through 1 year for the main cohort are shown in Figure 5 through Figure 8, respectively. The mean and peak RVOT gradients remained largely stable through 1 year post implant (9.7 mmHg and 17.9 mmHg, respectively, at 1 year). The proportion of patients with total PR \geq moderate decreased from 100% to 9.6% at 1 year. The proportion of patients with paravalvular regurgitation \geq moderate was 1.7% at 30 days, and 0% at both 6 months and 1 year.




Note: Line plot with mean and standard error. The total number of patients at each visit time point only counted the patients with evaluable values.

Figure 5: Mean RVOT Gradient (VI Population) - Main Cohort




Note: Line plot with mean and standard error. The total number of patients at each visit time point only counted the patients with evaluable values.

Figure 6: Peak RVOT Gradient (VI Population) - Main Cohort



Note: The total number of patients at each visit time point only counted the patients with evaluable values.

Figure 7: Total Pulmonary Regurgitation (VI Population) - Main Cohort



Note: The total number of patients at each visit time point only counted the patients with evaluable values.

Figure 8: Paravalvular Regurgitation (VI Population) - Main Cohort

NYHA Functional Class

The NYHA classifications by visit are presented for the main cohort in Figure 9. At baseline, 91.7% of patients in the main cohort were in NYHA Class I/II, which increased to 100% at 30 days and 6 months and 98.1% at 1 year.





Figure 9: NYHA Class by Visit (VI Population) - Main Cohort


Characterization of Right Ventricular Remodeling

Right ventricular remodeling was characterized via magnetic resonance imaging (MRI) and computed tomography (CT) in the main cohort. Right ventricular end diastolic volume (RVEDV), RVEDV index, and main pulmonary artery regurgitant fraction at baseline and 1 year are presented in Figure 10 through Figure 12, respectively. The RVEDV decreased from 295.9 ml to 220.4 ml, with the corresponding RVEDV index decreasing from 162.7 ml/m² to 118.9 ml/m². The main pulmonary artery regurgitant fraction decreased from 47.4% to 4.1%.




Note: The total number of patients at each visit time point only counted the patients with evaluable paired values.

Figure 10: Right Ventricular End Diastolic Volume (VI Population) - Main Cohort



Note: The total number of patients at each visit time point only counted the patients with evaluable paired values.

Figure 11: Right Ventricular End Diastolic Volume Index (VI Population) - Main Cohort



Note: The total number of patients at each visit time point only counted the patients with evaluable paired values.

Figure 12: Main Pulmonary Artery Regurgitant Fraction (VI Population) - Main Cohort

(3) Adverse Events

Kaplan-Meier estimates of the CEC-adjudicated adverse events through 1 year for the main cohort and through 6 months for the PDS registry cohort are presented in Table 14 and Table 15 respectively.

Table 14: CEC-Adjudicated Adverse Events Through 1 Year (AT Population) - Main Cohort

Event	Summary Statistics*		
	30 Days (N=60)	6 Months (N=59)	1 Year (N=49)
All-cause death	0.0% (0, 0)	0.0% (0, 0)	0.0% (0, 0)
Reintervention	0.0% (0, 0)	0.0% (0, 0)	0.0% (0, 0)
Arrhythmia	33.3% (21, 20)	33.3% (21, 20)	33.3% (21, 20)
Permanent pacemaker	0.0% (0, 0)	0.0% (0, 0)	0.0% (0, 0)
Acute kidney injury	0.0% (0, 0)	0.0% (0, 0)	0.0% (0, 0)
Bleeding	18.3% (12, 11)	21.7% (14, 13)	23.5% (16, 14)
Life threatening or disabling	0.0% (0, 0)	1.7% (1, 1)	3.5% (2, 2)
Major	1.7% (1, 1)	1.7% (1, 1)	1.7% (1, 1)
Minor	16.7% (11, 10)	18.4% (12, 11)	20.1% (13, 12)
Coronary artery compression	0.0% (0, 0)	0.0% (0, 0)	0.0% (0, 0)
Endocarditis	0.0% (0, 0)	0.0% (0, 0)	0.0% (0, 0)
Myocardial infarction	0.0% (0, 0)	0.0% (0, 0)	0.0% (0, 0)
Pulmonary embolism	0.0% (0, 0)	0.0% (0, 0)	0.0% (0, 0)
Stroke	0.0% (0, 0)	0.0% (0, 0)	0.0% (0, 0)
Transient ischemic attack	0.0% (0, 0)	0.0% (0, 0)	0.0% (0, 0)
Vascular injury or access site complication	5.0% (3, 3)	5.0% (3, 3)	6.8% (4, 4)
Major	0.0% (0, 0)	0.0% (0, 0)	1.8% (1, 1)
Minor	5.0% (3, 3)	5.0% (3, 3)	5.0% (3, 3)

*Kaplan-Meier estimate (no. events, no. patients with event)

Table 15: CEC-Adjudicated Adverse Events Through 6 Months (AT Population) - PDS Registry

Event	Summary Statistics*	
	30 Days (N=24)	6 Months (N=24)
All-cause death	4.0% (1, 1)	4.0% (1, 1)
Cardiovascular	0.0% (0, 0)	0.0% (0, 0)
Non-Cardiovascular	4.0% (1, 1)	4.0% (1, 1)
Reintervention	0.0% (0, 0)	0.0% (0, 0)
Arrhythmia	48.0% (15, 12)	48.0% (15, 12)
Permanent pacemaker	0.0% (0, 0)	0.0% (0, 0)
Acute kidney injury	0.0% (0, 0)	0.0% (0, 0)
Bleeding	20.0% (6, 5)	20.0% (6, 5)
Life threatening or disabling	0.0% (0, 0)	0.0% (0, 0)
Major	0.0% (0, 0)	0.0% (0, 0)
Minor	20.0% (6, 5)	20.0% (6, 5)
Coronary artery compression	0.0% (0, 0)	0.0% (0, 0)
Endocarditis	0.0% (0, 0)	0.0% (0, 0)
Myocardial infarction	0.0% (0, 0)	0.0% (0, 0)
Pulmonary embolism	0.0% (0, 0)	0.0% (0, 0)
Stroke	0.0% (0, 0)	0.0% (0, 0)
Transient ischemic attack	0.0% (0, 0)	0.0% (0, 0)

Event	Summary Statistics*	
	30 Days (N=24)	6 Months (N=24)
Vascular injury or access site complication	8.0% (4, 2)	8.0% (4, 2)
Major	0.0% (0, 0)	0.0% (0, 0)
Minor	8.0% (4, 2)	8.0% (4, 2)

*Kaplan-Meier estimate (no. events, no. patients with event)

(4) Other Study Observations

Procedural Information

Procedural data for the main cohort and PDS registry cohort are summarized in Table 16. Concomitant Alterra adaptive prestant and SAPIEN 3 THV procedures were performed on the majority of patients (98.3% for the main cohort & 100% for PDS registry cohort).

Table 16: Procedural Data (AT Population)

Variable	Summary Statistics*	
	Main Cohort (N=60)	PDS Registry (N=25)
Procedure type		
Staged procedure	1.7% (1/60)	0.0% (0/25)
Prestent procedure sheath time (min)	61.0	N/A
SAPIEN 3 procedure sheath time (min)	23.0	N/A
Concomitant Alterra adaptive prestant + SAPIEN 3 THV procedure	98.3% (59/60)	100.0% (25/25)
Procedure sheath time (min)	66.8 ± 4.73 (59)	58.2 ± 8.42 (25)
Alterra adaptive prestant procedure complications	3.3% (2/60)	0.0% (0/25)
SAPIEN 3 procedure complications	10.0% (6/60)	8.0% (2/25)
Total fluoroscopy time	37.2 ± 3.04 (60)	38.0 ± 4.88 (25)
Alterra adaptive prestant procedure post-dilatation performed	0.0% (0/60)	0.0% (0/25)
SAPIEN 3 procedure post-dilatation performed	11.7% (7/60)	0.0% (0/25)
Alterra adaptive prestant implanted in the intended location at the time the patient left the procedure room	100.0% (60/60)	100.0% (25/25)
SAPIEN 3 THV implanted in the intended location at the time the patient left the procedure room	100.0% (60/60)	100.0% (25/25)
Single SAPIEN 3 THV implanted	96.7% (58/60)	100.0% (25/25)

*Continuous measures - Mean ± SD (total no.); categorical measures - % (no./total no.)

CT Core Laboratory Findings

The results of an imaging assessment by the CT Core Laboratory through 1 year for the main cohort and through 30 days for the PDS registry cohort are presented in Table 17 and Table 18, respectively. There were no device reinterventions associated with these findings.

Table 17: CT Core Laboratory Findings (VI Population) - Main Cohort

Finding	Summary Statistics*	
	30 Days (N=60)	1 Year (N=55)
Alterra Adaptive Prestent penetration [†]		
Minor penetration - into adjacent vasculature or cardiac structure without extravasation, pseudoaneurysm, or erosion	2.6% (1/39)	5.3% (1/19)

Finding	Summary Statistics*	
	30 Days (N=60)	1 Year (N=55)
Major penetration - protrusion into surrounding tissue with blood pooling, or erosion, or pseudoaneurysm	0.0% (0/39)	0.0% (0/19)
Pedunculated mobile mass [†]	2.6% (1/39)	0.0% (0/19)
Alterra Adaptive Prestent fracture [‡]		
Fracture not requiring intervention	6.7% (4/60)	21.8% (12/55)
Fracture requiring intervention	0.0% (0/60)	0.0% (0/55)
SAPIEN 3 valve frame fracture [‡]	0.0% (0/60)	0.0% (0/55)

*Rate (no./total no.)

[†]Only included patients with evaluable images at visit time point.

[‡]Fracture was determined by either chest x-ray or fluoroscopy.

Table 18: CT Core Laboratory Findings (VI Population) - PDS Registry

Finding	Summary Statistics*
	30 Days (N=25)
Alterra Adaptive Prestent penetration [†]	
Minor penetration - into adjacent vasculature or cardiac structure without extravasation, pseudoaneurysm, or erosion	8.7% (2/23)
Major penetration - protrusion into surrounding tissue with blood pooling, or erosion, or pseudoaneurysm	0.0% (0/23)
Pedunculated mobile mass [†]	4.3% (1/23)
Alterra Adaptive Prestent fracture [‡]	
Fracture not requiring intervention	20.0% (5/25)
Fracture requiring intervention	0.0% (0/25)
SAPIEN 3 valve frame fracture [‡]	0.0% (0/25)

*Rate (no./total no.)

[†]Only included patients with evaluable images at visit time point.

[‡]Fracture was determined by either chest x-ray or fluoroscopy.



Edwards

2025-07
10043118003 A
© Copyright 2025, Edwards Lifesciences LLC
All rights reserved

Manufacturer 
Edwards Lifesciences LLC
One Edwards Way
Irvine, CA 92614 USA

Telephone +1.949.250.2500
+1.800.424.3278
FAX +1.949.250.2525

Web IFU